I. McNeish

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma

This study shows that combining RBM39 degraders with PARP inhibitors improves PARP inhibitor response in ovarian cancer, regardless of BRCA1/2 status.

Dual G9A and EZH2 inhibition stimulates an anti-tumour immune response in ovarian high-grade serous carcinoma

This study shows that dual inhibition of G9A and EZH2 in ovarian cancer enhances anti-tumour immune responses by altering the immune microenvironment and reducing tumour growth.

The genomic landscape of early stage ovarian high grade serous carcinoma

This study compares genomic features of early and late stage high grade serous ovarian carcinoma, finding no unique mutations or focal copy number alterations but noting differences in ploidy and copy number signatures.

Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy

This study identifies N-MYC pathway activation and susceptibility to EMT-targeting therapy in ovarian carcinosarcoma using genomic and pre-clinical models.

Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancer

This study shows that somatic copy number alterations in driver genes correlate with drug response in HGSOC spheroid models and clinical settings.